[Hankyung] C&R Research helps develop treatments for rare diseases through ‘external control group’
C&R Research, Korea’s first contract research organization (CRO) company, supports the development of treatments for rare and incurable diseases using an external control group.
C&R Research announced on the 27th that it was selected for a project contested by the Smart Clinical Trial New Technology Development Research Group and will cooperate with Kakao Healthcare and Kyung Hee Medical Center to build and utilize an external control group by 2027.
The three organizations plan to standardize clinical data for each disease and establish an external control group. To this end, C&R Research plans to visit the International Clinical Data Standards Consortium in October and consult with officials from the U.S. Food and Drug Administration (FDA).
